---
figid: PMC10216286__cancers-15-02752-g003
figtitle: TRAIL and DR5 agonist antibodies increase PD-L1 expression
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10216286
filename: cancers-15-02752-g003.jpg
figlink: /pmc/articles/PMC10216286/figure/F3
number: F3
caption: TRAIL and DR5 agonist antibodies increase PD-L1 expression. TRAIL can induce
  PD-L1 expression by activating the ERK and STAT3 pathways or inhibiting miR-429.
  DR5 agonist antibodies can induce PD-L1 expression by activating ROCK1. Induction
  of PD-L1 then results in EMT, cell survival, immune evasion, and resistance to TRAIL
papertitle: The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer
reftext: Julio M. Pimentel, et al. Cancers (Basel). 2023 May;15(10).
year: '2023'
doi: 10.3390/cancers15102752
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: TRAIL | apoptosis | resistance | immunosurveillance | PD-L1
automl_pathway: 0.9456525
figid_alias: PMC10216286__F3
figtype: Figure
redirect_from: /figures/PMC10216286__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10216286__cancers-15-02752-g003.html
  '@type': Dataset
  description: TRAIL and DR5 agonist antibodies increase PD-L1 expression. TRAIL can
    induce PD-L1 expression by activating the ERK and STAT3 pathways or inhibiting
    miR-429. DR5 agonist antibodies can induce PD-L1 expression by activating ROCK1.
    Induction of PD-L1 then results in EMT, cell survival, immune evasion, and resistance
    to TRAIL
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TNFSF10
  - TNFRSF10B
  - EPHB2
  - MAPK1
  - MAPK3
  - MIR429
  - STAT3
  - ROCK1
  - CD274
  - ITK
  - SLC22A3
---
